Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gas Chromatography–Mass Spectrometry (GC–MS)01:14

Gas Chromatography–Mass Spectrometry (GC–MS)

4.0K
Gas chromatography–mass spectrometry (GC–MS) is the combination of analytical techniques of gas chromatography and mass spectrometry in a single instrument for analyzing a mixture of compounds. The gas chromatograph separates the compounds in the mixture, and the mass spectrometer analyzes each compound separately to determine the molecular masses and molecular structures.
A gas chromatograph consists of a long, narrow capillary column with a polysiloxane coating on the inner wall....
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance).

Blood advances·2026
Same author

Best Practices and Key Barriers for Amyloidosis Patient Care at US Specialized Amyloidosis Centers: An Analysis by ARC-ASPIRE.

Clinical Medicine Insights. Cardiology·2026
Same author

Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.

Blood cancer journal·2026
Same author

Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Hepatic response criteria in light chain amyloidosis: a multicenter validation study.

Haematologica·2026

Related Experiment Video

Updated: Jun 5, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K

MGCS: where do we stand today?

David Iberri1, Michaela Liedtke1

  • 1Stanford University School of Medicine, Division of Hematology, Stanford, CA.

Hematology. American Society of Hematology. Education Program
|December 7, 2024
PubMed
Summary

Monoclonal gammopathies of clinical significance (MGCS) involve B-cell or plasma-cell clones producing toxic proteins that harm organs. This review focuses on hematologic and multi-organ MGCS, distinct from renal, neurologic, and cutaneous forms.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Monoclonal gammopathies of clinical significance (MGCS) are disorders caused by toxic monoclonal immunoglobulin production from B-cell or plasma-cell clones.
  • MGCS leads to end-organ dysfunction and requires clinicopathologic diagnosis.
  • Commonly recognized MGCS include renal, neurologic, and cutaneous syndromes.

Purpose of the Study:

  • To focus on hematologic and multi-organ Monoclonal Gammopathies of Clinical Significance (MGCS).
  • To differentiate these from other MGCS syndromes like renal, neurologic, and cutaneous.

Main Methods:

  • Review of existing literature and clinical data on MGCS.
  • Focus on diagnostic criteria and clinical presentation of hematologic and multi-organ MGCS.

More Related Videos

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

9.7K
Mesenchymal Stem Cell Regulation of Macrophage Phagocytosis; Quantitation and Imaging
09:10

Mesenchymal Stem Cell Regulation of Macrophage Phagocytosis; Quantitation and Imaging

Published on: July 16, 2021

3.1K

Related Experiment Videos

Last Updated: Jun 5, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K
Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

9.7K
Mesenchymal Stem Cell Regulation of Macrophage Phagocytosis; Quantitation and Imaging
09:10

Mesenchymal Stem Cell Regulation of Macrophage Phagocytosis; Quantitation and Imaging

Published on: July 16, 2021

3.1K
  • Discussion of therapeutic approaches targeting clonal populations and related pathways.

    • Main Results:

    • Hematologic and multi-organ MGCS are increasingly recognized clinical entities.
    • Therapies targeting the underlying clonal population are primary treatment strategies.
    • Emerging therapies include immunoglobulin-targeting agents, complement antagonists, and cytokine antagonists for selected cases.

    Conclusions:

    • Hematologic and multi-organ MGCS represent significant clinical challenges.
    • Understanding the heterogeneity of MGCS is crucial for diagnosis and management.
    • Targeted therapies offer potential for managing specific MGCS syndromes, though often temporizing.